MSH2 and cancer: Endometrial cancer is the second most common cancer in women with LS, occurring in up to 54% of women with MLH1 and up to 57% of women with MSH2 or EPCAM mutations, while a lower risk (13–26%) is observed in PMS2 mutation carriers [14,15,18,19,21,22].